Celyad

    [td_text_with_title custom_title=”Company description”]Celyad – previously Cardio3 BioSciences – is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing  clinical stage cell therapies in cardiology[/td_text_with_title]
    [td_text_with_title custom_title=”Latest post”]
    celyad_ipo

    Celyad

    Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, raised $100 million by offering 1.5 million shares (upsized from 1.4 million) at $68.56, below the $71.13 closing price on Thursday on the Euronext. The offering consisted of 1.2 million ADSs, which will trade on the NASDAQ under the symbol CYAD, and 0.3 […]

    0 comments
    celyad

    Celyad files for a $115 million IPO

    Celyad, a Belgian biotech developing gene therapies for cardiovascular diseases and cancer, filed on Monday with the SEC to raise up to $115 million in an initial public offering. Celyad’s stock is currently traded on the Euronext Brussels and Euronext Paris under the symbol CYAD. Its market cap is about €450 million and it gained 5% […]

    0 comments
    [/td_text_with_title]